REG - Hutchmed China Ltd - Appointment of Independent NED

HUTCHMED (China)Announcement

10/05/2023 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230510:nRSJ9369Ya&default-theme=true

RNS Number : 9369Y  Hutchmed (China) Limited  10 May 2023

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees

 

 

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, May 10, 2023: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the "Company")
(Nasdaq/AIM:HCM, HKEX:13) today announces that that Professor Solange Peters
is appointed as an Independent Non-executive Director, member of the Technical
Committee and member of the Audit Committee of the Company with effect from
the conclusion of the annual general meeting of the Company to be held on May
12, 2023. Professor Peters is a renowned scientist and educator who possesses
expertise and extensive experience in oncology and immunology. The Board of
HUTCHMED is of the view that Professor Peters will make significant
contributions to the Company.

 

Mr Simon To, Chairman of HUTCHMED said "On behalf of the Board, I would like
to extend a warm welcome to Professor Peters to the Company.  We believe that
her expertise in biopharmaceutical research in oncology and immunology would
be of immense value to the Company and she would be instrumental in assisting
the Company in achieving its goals."

 

Professor Peters, aged 50, is the chair of medical oncology and thoracic
malignancies in the Department of Oncology at the University Hospital of
Lausanne in Lausanne, Switzerland. After completing her clinical education in
medical oncology and molecular biology in Switzerland and Italy, she
specialized in thoracic tumors, lung cancer, and pleural tumors. Professor
Peters was the youngest president of the European Society for Medical Oncology
(ESMO) for an extended period of three years from 2020 to 2022, and she is
active in the educational programmes of ESMO, where she created the Women for
Oncology Committee. Professor Peters was also a member of the board of
directors of the International Association for the Study of Lung Cancer
(IASLC) from 2013 to 2017.

 

Professor Peters is currently in charge of teaching and patient care in
thoracic malignancies at Lausanne University, where she is building a
translational programme in collaboration with the Swiss Federal Institute of
Technology and the Ludwig Institute. Her main fields of interest are new
biomarker discovery and validation in preclinical and clinical settings,
multimodality strategies for locally advanced non-small cell lung cancer
(NSCLC), as well as cancer immunotherapy. Her current research projects are
mainly focused on innovative immunotherapy combinations and new
immuno-modulating treatments across thoracic malignancies. She acts as the
local principal investigator (PI) for lung trials opened at Lausanne Cancer
Centre and is a co-PI of several other trials.

 

Professor Peters acts as the scientific committee chair and foundation council
member of the ETOP IBCSG Partners Foundation. She was recently nominated as
the strategic advisory board president of the Paris Saclay Cancer Cluster and
is part of the board of directors of the Swiss National Cancer League. She is
also the president of International Cancer Foundation. Professor Peters is
also an independent director of Galenica AG, which is listed on the SIX Swiss
Exchange.

 

Professor Peters has authored more than 500 peer-reviewed manuscripts and book
chapters, acts as Associate Editor of the Annals of Oncology, Deputy Editor of
Lung Cancer, and serves on the editorial board of several other oncology
journals. She was the deputy editor of the Journal of Thoracic Oncology for
ten years. She received both her doctorate in medicine and PhD from the
University Hospital of Lausanne.

 

Save for the appointments listed above, Professor Peters has held no other
directorships or partnerships during the period of five years prior to her
appointment as a director of HUTCHMED. She does not have any relationship with
any Directors, senior management or substantial or controlling shareholders of
HUTCHMED. Professor Peters does not have any interest in the ordinary shares
of HUTCHMED within the meaning of Part XV of the Securities and Futures
Ordinance (Cap.571 of the Laws of Hong Kong).  The initial term of the
appointment of Professor Peters as an Independent Non-executive Director of
the Company shall end at the next general meeting of the Company, subject to
retirement in accordance with the Articles of Association of the Company and
applicable legal and regulatory requirements. The initial term shall be
automatically renewed for successive 12-month periods, unless she is not
re-elected at the next general meeting or her appointment is otherwise
terminated earlier by either party in writing. The director's fees of
Professor Peters as an Independent Non-executive Director, member of the
Technical Committee and member of the Audit Committee of the Company under her
appointment letter are US$76,000, US$8,000 and US$13,500 per annum
respectively.  Such fees are subject to review from time to time and
proration for any incomplete year of service.

 

Save for the information disclosed above, there is no other information in
relation to Professor Peters that is required to be disclosed pursuant to Rule
17 and Schedule 2(g) of the AІM Rules for Companies or Rule 13.51(2) of the
HK Listing Rules and there are no other matters concerning the appointment of
Professor Peters that are required to be brought to the attention of the
shareholders of HUTCHMED.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

 

Forward-Looking Statements

 

This announcement contains forward-looking statements within the meaning of
the "safe harbor" provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events. Forward-looking statements involve risks
and uncertainties. Such risks and uncertainties include, among other things,
the risk that current or future appointees to HUTCHMED's board of directors
are not effective in their respective positions, the difficulty in locating
and recruiting suitable candidates for its board of directors and the
management difficulties which may arise from changes in HUTCHMED's board of
directors. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the U.S. Securities and Exchange Commission, on AІM and with The
Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to
update or revise the information contained in this announcement, whether as a
result of new information, future events or circumstances or otherwise.

 

 

CONTACTS

 

 Investor Enquiries
 Mark Lee, Senior Vice President                                  +852 2121 8200
 Annie Cheng, Vice President                                      +1 (973) 306-4490

 Media Enquiries
 Americas - Brad Miles,                                           +1 (917) 570 7340 (Mobile) / bmiles@s (mailto:bmiles@soleburystrat.com)

Solebury Strategic Communications                               oleburystrat (mailto:bmiles@soleburystrat.com) .com
                                                                  (mailto:bmiles@soleburystrat.com)
 Europe - Ben Atwell / Alex Shaw,                                 +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                                                  +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                  (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi, Brunswick                                        +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                  (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon  +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXSEFLDDEEA